Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives $41.50 Average PT from Analysts

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been given an average recommendation of “Moderate Buy” by the five research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $41.50.

Several research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. Westpark Capital began coverage on Aligos Therapeutics in a research report on Thursday. They issued a “buy” rating and a $48.00 target price on the stock. Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. Finally, UBS Group initiated coverage on shares of Aligos Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price objective on the stock.

Aligos Therapeutics Price Performance

Shares of ALGS stock opened at $6.66 on Thursday. The firm’s 50-day moving average is $7.30 and its two-hundred day moving average is $8.71. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $13.69. The company has a market capitalization of $41.23 million, a PE ratio of -0.78 and a beta of 2.67.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share for the quarter, beating the consensus estimate of ($2.09) by $0.18. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.27 million. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. Sell-side analysts forecast that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of Aligos Therapeutics by 21.3% in the second quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock valued at $246,000 after buying an additional 5,978 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after acquiring an additional 9,000 shares in the last quarter. NorthCrest Asset Manangement LLC acquired a new position in Aligos Therapeutics during the 3rd quarter worth about $98,000. Susquehanna International Group LLP purchased a new position in Aligos Therapeutics during the 3rd quarter valued at about $99,000. Finally, LPL Financial LLC grew its position in Aligos Therapeutics by 19.7% in the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock valued at $615,000 after acquiring an additional 10,880 shares in the last quarter. 60.43% of the stock is owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.